2020/09/16 by Lennard Ostendorf, Marie Burns, Marie E. Burns +17 · 3 citations
Medicine · Immunology and Microbiology · #Systemic Lupus Erythematosus Research #Monoclonal and Polyclonal Antibodies Research #T-cell and B-cell Immunology
paper · doi:10.1056/nejmoa2023325
Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are unresponsive to standard immunosuppression. We describe the use of daratumumab that induced substantial clinical responses in two patients with life-threatening lupus, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor. Significant depletion of long-lived plasma cells, reduction of interferon type I activity, and down-regulation of T-cell transcripts associated with chronic inflammation were documented. (Supported by the Deutsche Forschungsgemeinschaft and others.).